Build the capital's medical and health industry "nuclear explosion"

The park has also cooperated with a number of enterprises and institutions to build a public platform, and cooperated with Huahui Anjian (Beijing) Biotechnology Co., LTD., to jointly build an intelligent GMP pilot platform for antibody drugs to help startups save research and development costs and shorten the research and development cycle. Cooperate with the Cell and Gene Therapy Innovation Center (CGTIC) of Tsinghua Institute of Technology to build a platform for cell and gene therapy research and development and pilot test, provide a complete industrial chain of cell and gene therapy drug research and development from preclinical research, pilot test to production, and accelerate the research and development process by combining artificial intelligence, 5G, automation and other technologies.

Build a global innovation network

Zhongguancun Life Science Park has gathered a group of high-level research and development institutions, gathered a group of top scientists and hundreds of high-level talents, and initially formed the whole industrial chain gathering trend of basic research, pilot research and development, production and circulation, and terminal medical treatment.

In the field of new drug research and development, a number of key enterprises such as Beigene, Novo Nordisk and Novo Nordisk have been brought together. In the field of innovative medical devices, a number of well-known enterprises such as Boao Bio, Wantai Bio and Mindray Medical, which are owned by Academician Cheng Jing, have settled in. The frontier field of gene and cell therapy has brought together a number of start-up biotechnology companies with explosive potential, such as Hopson Gene, Boya Jiyin, Huaxia Yingtai, etc. The field of precision medicine has brought together a large number of innovative enterprises with original and important achievements in molecular diagnostic gene sequencing, such as Novo Zhiyuan, Berry Hekang, and Panson.

The park has also gathered a number of service-oriented enterprises that do R&D outsourcing and production tool outsourcing for scientists, such as CRO enterprises such as Baonuo Technology, Pharmaron, and Junke Huasan. The second phase of Zhongguancun Life Science Park also gathers Peking University International Hospital (comprehensive Grade III), Peking University Sixth Hospital, Peking University Rehabilitation Hospital, and Hope Thyroid Hospital.

After more than 20 years of cultivation and development, the innovation achievements of Zhongguancun Life Science Park continue to emerge, and a large number of original new drugs have been launched and entered the world. In 2020, Zebutinib independently developed by Beigene and Obutinib independently developed by Notech Health were officially approved for listing, and these two first-class innovative drugs were sold in the United States.